Five analytics firms launch RWE lobbying group to press Congress, FDA on guidance, Cures 2.0
With around 75% of all new drug approvals in 2020 including real world evidence in their submissions to FDA, data and analytics firms Aetion, Flatiron Health (an independent affiliate of Roche), IQVIA, Syapse, and Tempus are gearing up to press Congress and the FDA even further on using RWE to accelerate drug development.
The companies all chipped in to hire the lobbying firm Covington to run the new RWE Alliance. Ken Tarkoff, CEO of Syapse, told Endpoints News in an interview that as the organization grows over time, the alliance is hoping new companies will pay to be members of the alliance to further the cause.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.